Pipeline

Dawah Pharmaceuticals Inc. is advancing global healthcare through a robust pipeline of essential drugs in collaboration with top-tier international Contract Manufacturing Organizations (CMOs). By leveraging strategic overseas partnerships, we ensure the efficient delivery of FDA-compliant drugs that address critical therapeutic needs across a wide range of disease states.

Antipsychotics Help manage both chronic and acute mental health disorders to stabilize patients
Paralytics Used to facilitate anesthesia and ensure patient immobilization during surgery or critical care
Antibiotics Target and treat severe bacterial infections, including resistant strains
Oncology Drugs Provide innovative and life-saving treatments for various types of cancer
Antifungals Treat systemic and invasive fungal infections effectively.

Ophthalmics

Anti-inflammatory Agents: Reducing inflammation in ocular diseases.
Antibiotic-Corticosteroid Combinations: Treating bacterial infections with concurrent inflammation.
Antihistamines: Providing relief from allergic conjunctivitis and related ocular allergies.

Bags and (TPN)

Pain Management: Offering intravenous acetaminophen for effective pain and fever control.
Critical Care Solutions: Including dopamine and electrolytes for emergency and intensive care applications.
Nutritional Support: High-use TPN formulations for patients with impaired oral intake.

Overseas Partnerships

Dawah Pharmaceuticals has meticulously evaluated over 30 global CMOs and strategically partnered with two industry leaders based overseas. These partnerships are integral to our operations
Optimize manufacturing costs with contributions of the sterile production cost by our selected CMOs.

Activities Provided by CMOs

Comprehensive Development: Formulation, process design, and analytical testing.
Regulatory Preparedness: Manufacturing registration batches and compiling FDA dossiers.
Stability Testing: Ensuring efficacy and safety over extended periods.

Commitment to Excellence

Our partnerships empower Dawah Pharmaceuticals to maintain agility while delivering high-quality, FDA-compliant drugs to address critical healthcare needs. By continuously assessing market trends and patient requirements, we are committed to expanding our pipeline and improving global access to essential medications.

Here is a list of the drugs we plan to bring to the U.S. market via JV, along with their indications and projected launch years.

2026–2027

Bacterial infections (oral antibiotic)

2028

Type 2 diabetes, weight management

2028–2029

Acute heart failure, cardiac stress testing

2028–2029

Edema, congestive heart failure, hypertension

2028–2029

Short-term pain relief (injectable NSAID)

2028–2029

Gallstone dissolution, primary biliary cholangitis

2027–2028

Antiplatelet (cardiovascular diseases)

2028–2029

Sedation in intensive care and surgical settings

2028–2029

Induction of general anesthesia

2028–2029

Short-term pain relief (injectable NSAID)

2028–2029

Alzheimer’s disease

2031

Chemotherapy, autoimmune diseases (oncology)

Pipeline

Sterile Injectables

Commitment to Excellence